The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial.
In the randomized, placebo-controlled, physician-blinded Canadian cooperative trial of cyclophosphamide and plasma exchange, neither active treatment regimens (group I: i.v. cyclophosphamide and prednisone; group II: weekly plasma exchange, oral cyclophosphamide, and prednisone) were superior to pla...
| Váldodahkkit: | , , , , , |
|---|---|
| Materiálatiipa: | Journal article |
| Giella: | English |
| Almmustuhtton: |
1994
|
| _version_ | 1826294123476287488 |
|---|---|
| author | Noseworthy, J Ebers, G Vandervoort, M Farquhar, R Yetisir, E Roberts, R |
| author_facet | Noseworthy, J Ebers, G Vandervoort, M Farquhar, R Yetisir, E Roberts, R |
| author_sort | Noseworthy, J |
| collection | OXFORD |
| description | In the randomized, placebo-controlled, physician-blinded Canadian cooperative trial of cyclophosphamide and plasma exchange, neither active treatment regimens (group I: i.v. cyclophosphamide and prednisone; group II: weekly plasma exchange, oral cyclophosphamide, and prednisone) were superior to placebo (group III: sham plasma exchange and placebo medications) using the blinded, evaluating neurologists' assessments of disease course (primary analysis). All patients were examined by both a blinded and an unblinded neurologist at each assessment in this trial. We compared the blinded and unblinded neurologists' judgment of treatment response and analyzed the clinical behavior of patients who correctly guessed their treatment. The unblinded (but not the blinded) neurologists' scores demonstrated an apparent treatment benefit at 6, 12, and 24 months for the group II patients (not group I or placebo; p < 0.05, two-tailed). There were no significant differences in the time to treatment failure or in the proportions of patients improved, stable, or worse between the group II and group III patients who correctly guessed their treatment assignments and those who did not. Physician blinding prevented an erroneous conclusion about treatment efficacy (false positive, type 1 error). |
| first_indexed | 2024-03-07T03:40:47Z |
| format | Journal article |
| id | oxford-uuid:bdd15c6e-ffb0-4f22-bd3c-24dc5f9d26fe |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:40:47Z |
| publishDate | 1994 |
| record_format | dspace |
| spelling | oxford-uuid:bdd15c6e-ffb0-4f22-bd3c-24dc5f9d26fe2022-03-27T05:34:38ZThe impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bdd15c6e-ffb0-4f22-bd3c-24dc5f9d26feEnglishSymplectic Elements at Oxford1994Noseworthy, JEbers, GVandervoort, MFarquhar, RYetisir, ERoberts, RIn the randomized, placebo-controlled, physician-blinded Canadian cooperative trial of cyclophosphamide and plasma exchange, neither active treatment regimens (group I: i.v. cyclophosphamide and prednisone; group II: weekly plasma exchange, oral cyclophosphamide, and prednisone) were superior to placebo (group III: sham plasma exchange and placebo medications) using the blinded, evaluating neurologists' assessments of disease course (primary analysis). All patients were examined by both a blinded and an unblinded neurologist at each assessment in this trial. We compared the blinded and unblinded neurologists' judgment of treatment response and analyzed the clinical behavior of patients who correctly guessed their treatment. The unblinded (but not the blinded) neurologists' scores demonstrated an apparent treatment benefit at 6, 12, and 24 months for the group II patients (not group I or placebo; p < 0.05, two-tailed). There were no significant differences in the time to treatment failure or in the proportions of patients improved, stable, or worse between the group II and group III patients who correctly guessed their treatment assignments and those who did not. Physician blinding prevented an erroneous conclusion about treatment efficacy (false positive, type 1 error). |
| spellingShingle | Noseworthy, J Ebers, G Vandervoort, M Farquhar, R Yetisir, E Roberts, R The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. |
| title | The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. |
| title_full | The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. |
| title_fullStr | The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. |
| title_full_unstemmed | The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. |
| title_short | The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. |
| title_sort | impact of blinding on the results of a randomized placebo controlled multiple sclerosis clinical trial |
| work_keys_str_mv | AT noseworthyj theimpactofblindingontheresultsofarandomizedplacebocontrolledmultiplesclerosisclinicaltrial AT ebersg theimpactofblindingontheresultsofarandomizedplacebocontrolledmultiplesclerosisclinicaltrial AT vandervoortm theimpactofblindingontheresultsofarandomizedplacebocontrolledmultiplesclerosisclinicaltrial AT farquharr theimpactofblindingontheresultsofarandomizedplacebocontrolledmultiplesclerosisclinicaltrial AT yetisire theimpactofblindingontheresultsofarandomizedplacebocontrolledmultiplesclerosisclinicaltrial AT robertsr theimpactofblindingontheresultsofarandomizedplacebocontrolledmultiplesclerosisclinicaltrial AT noseworthyj impactofblindingontheresultsofarandomizedplacebocontrolledmultiplesclerosisclinicaltrial AT ebersg impactofblindingontheresultsofarandomizedplacebocontrolledmultiplesclerosisclinicaltrial AT vandervoortm impactofblindingontheresultsofarandomizedplacebocontrolledmultiplesclerosisclinicaltrial AT farquharr impactofblindingontheresultsofarandomizedplacebocontrolledmultiplesclerosisclinicaltrial AT yetisire impactofblindingontheresultsofarandomizedplacebocontrolledmultiplesclerosisclinicaltrial AT robertsr impactofblindingontheresultsofarandomizedplacebocontrolledmultiplesclerosisclinicaltrial |